Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Observational × neratinib × Clear all

Status

Not yet recruiting 2 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 14 Observational 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Blood Specimen Collection 112 Surveys and Questionnaires 69 Observation 42 Radiotherapy 39 Drug Therapy 33 Surgical Procedures, Operative 31 Biopsy 31 Specimen Handling 27 Data Collection 26 Magnetic Resonance Imaging 19 Interviews as Topic 19 Watchful Waiting 17 Liquid Biopsy 16 Magnetic Resonance Spectroscopy 15 Immune Checkpoint Inhibitors 15 Tomography, X-Ray Computed 13 Immunotherapy 13 pembrolizumab 12 Radiosurgery 11 Nivolumab 11 Neoadjuvant Therapy 11 Ultrasonography 10 Standard of Care 10 lenvatinib 9 Radiation 9 Carboplatin 9 trastuzumab deruxtecan 8 Transurethral Resection of Prostate 8 Tissue Banks 8 Endoscopic Mucosal Resection 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06693024 2024-11-20

NeraHER2

Peking University People's Hospital

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡